CD38 and plasma cell myeloma: <h4>Objectives</h4>The current study aims to evaluate the safety and efficacy of anti-CD38 monoclonal antibodies (mAbs) among patients with relapsed/refractory multiple myeloma (RRMM) through meta-analysis.<h4>Methods</h4>As of June 2023, we searched PubMed, Web of Science, Embase and the Cochrane Library.